Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03982030
Other study ID # IRB00054355
Secondary ID
Status Withdrawn
Phase Phase 4
First received
Last updated
Start date April 2023
Est. completion date July 2025

Study information

Verified date May 2023
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research is to determine if a new antibiotic called dalbavancin will work to treat and cure certain infections while reducing the need for daily antibiotics by vein.


Description:

A phase 4, single-center, pilot open-label trial assessing the safety and efficacy of dalbavancin in the outpatient therapy of susceptible gram-positive infections requiring prolonged intravenous therapy.


Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dalbavancin
Dalbavancin 1.5g IV at day 0, day 8-10

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Wake Forest University Health Sciences

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with resolution of infection Number of participants with no recurrent signs or symptom of infection Week 6
Secondary Number of participants with development of breakthrough infection - week 6 Number of participants with worsening signs or symptoms of primary infection or development of new infection. Week 6
Secondary Number of participants with development of breakthrough infection - Month 6 Number of participants with worsening signs or symptoms of primary infection or development of new infection. Month 6
Secondary Number of participants with hospital readmission - week 6 Number of participants readmitted for the primary infection under treatment or related complication. Week 6
Secondary Number of participants with hospital readmission - Month 6 Number of participants readmitted for the primary infection under treatment or related complication. Month 6
Secondary Number of participants with need for further surgical intervention - week 6 Number of participants that need surgical intervention for primary infection prior to end of study participation. Week 6
Secondary Number of participants with need for further surgical intervention - Month 6 Number of participants that need surgical intervention for primary infection prior to end of study participation. Month 6
Secondary Number of adverse events leading to discontinuation of study drug -week 6 Week 6
Secondary Number of adverse events leading to discontinuation of study drug - Month 6 Month 6
Secondary Number of participants loss to follow-up - week 6 Number of participants that fail to receive second planned dalbavacin dose and attend study visits.
failure to attend scheduled visits after receiving second dalbavancin dose
Week 6
Secondary Number of participants loss to follow-up - Month 6 Number of participants that fail to receive second planned dalbavacin dose and attend study visits.
failure to attend scheduled visits after receiving second dalbavancin dose
Month 6
Secondary Costs of antibiotic therapy Costs of antibiotic therapy will be measured by combined estimated total costs per participant of inpatient and outpatient antibiotic therapy. Month 6
Secondary Participant Study Questionnaire week 4 Participant satisfaction will be measured using the 5 point scale (4-strongly agree, 3-agree, 2 neutral, 1-disagree, and 0-strongly disagree). Higher scores denote better outcome. week 4
Secondary Participant Study Questionnaire week 24 Participant satisfaction will be measured using the 5 point scale (4-strongly agree, 3-agree, 2 neutral, 1-disagree, and 0-strongly disagree). Higher scores denote better outcome. Month 6
Secondary Number of participants with reported overdose Month 6
Secondary Number of participants with new enrollment in addiction treatment Month 6
Secondary Number of participants re-admitted for addiction-related issue Month 6
Secondary Time investment per patient required to follow this model Time investment per patient will be measured by combined time in minutes spent by study and clinical staff on addiction-related phone calls, paperwork and in-person appointments. 6 months
See also
  Status Clinical Trial Phase
Completed NCT01412801 - Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings Phase 2
Terminated NCT00108433 - Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections Phase 3
Completed NCT00501150 - Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections N/A
Not yet recruiting NCT06444802 - Model-informed Precision Dosing for Linezolid Phase 3
Terminated NCT00529282 - A Study of Ceftobiprole in Patients With Fever and Neutropenia. Phase 3
Completed NCT00079976 - Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA) Phase 3
Terminated NCT00835783 - Validation Study of Combined Positron Emission Tomography/Computer Tomography to Diagnose Infection and Inflammation N/A
Completed NCT00081744 - Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects Phase 3
Completed NCT03747497 - Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection Phase 2
Active, not recruiting NCT04911270 - Clinical Decision Support Tool for Vancomycin Dosing in Children N/A
Completed NCT02750761 - A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013) Phase 1
Completed NCT00406198 - Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis Phase 4
Completed NCT03560440 - Evaluation of the Dosing Regimen of Vancomycin in Pediatric Patients
Completed NCT00147511 - Time To Efficacy and Onset Of Action Of Linezolid Phase 4
Terminated NCT00240747 - Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients Phase 3
Not yet recruiting NCT04917380 - The Clinical Character,Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens.
Completed NCT00736554 - What is the Prevalence of Methicillin-Resistant Staphylococcus Aureus in Skin and Soft Tissue Infections Presenting to the Emergency Departments of a Canadian Academic Health Care Center? N/A
Completed NCT03361163 - Controlled Human Infection for Vaccination Against Streptococcus Pyogenes Phase 1
Completed NCT00167960 - Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit Phase 4
Completed NCT00874367 - Early-Onset Sepsis Surveillance Study N/A